tgfβ1

AXL-IN-13 is a potent and orally active AXL inhibitor with an IC50 of 1.6 nM and a Kd of 0.26 nM. It exhibits anticancer activity, reverses TGF-β1-induced epithelial-mesenchymal transition (EMT), and inhibits cancer cell migration and invasion.

TGFβ1-IN-2, a derivative of diarylacylhydrazones, effectively inhibits fibroblast activation and proliferation and holds potential for idiopathic pulmonary fibrosis (IPF) research [1].

TGFβ1-IN-3, a diarylhydrazone derivative, inhibits fibroblast activation and proliferation, positioning it as a candidate compound for the treatment of idiopathic pulmonary fibrosis (IPF).

TGFβ1-IN-1 is an orally active TGF-β1 inhibitor that inhibits the production of TGF-β1-induced fibrotic markers (α-SMA and fibronectin) and can be used for the study of cancer and autoimmune diseases.

Disitertide acetate (P144 acetate) is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide acetate is also a PI3K inhibitor and an apoptosis inducer.

Tubastatin inhibits TGF-β1-induced phosphorylation of S6K, HIF-1α expression and VEG F expression.Tubastatin inhibits TGF-β1-induced inhibition of LC3B-II, a marker of autophagosome formation.

Disitertide (P144) diammonium, a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor, is specifically engineered to prevent its receptor interaction. Additionally, it serves as a PI3K inhibitor and induces apoptosis, as evidenced by references [1] [2] [3] [4] [5].

Linavonkibart (SRK181) is a humanized antibody targeting TGFβ1 that blocks the release of TGF-β1 protein by specifically binding latent TGF-β1.

Fresolimumab (GC1008) is a specific human anti-transforming growth factor β monoclonal antibody that binds to the active forms of human TGFβ1, TGFβ2, and TGFβ3 and can be used to study focal segmental glomerulosclerosis and cancer in adults.

Livmoniplimab (ABBV-151; ARGX-115), a potent humanized monoclonal antibody targeting LRRC32 (GARP) TGFβ1, inhibits LRRC32-mediated activation of latent TGFβ1, showing promise for cancer research [1].

RU-301 is a novel pan-tam inhibitor

Disitertide (P144) TFA is a peptide-based inhibitor of transforming growth factor-beta 1 (TGF-β1), designed to prevent its interaction with the receptor, while also functioning as a PI3K inhibitor and promoting apoptosis [1] [2] [3] [4] [5].

Metelimumab (CAT-192), a human IgG4 monoclonal antibody, selectively neutralizes TGFβ1 [1].

Asiaticoside (Emdecassol) (Madecassol) is the active chemical component of the plant Centella asiatica. Asiaticoside is used to study potential treatments for wounds and burns.